<DOC>
	<DOCNO>NCT01752296</DOCNO>
	<brief_summary>Mucopolysaccharidosis IV , also know MPS IV Morquio disease , rare autosomal recessive genetic lysosomal storage disorder . Research thus far regard lysosomal storage disease ( LSDs ) general , include Morquio , primarily focus explore cause find treatment physical aspect various disease . Less attention pay psychological emotional toll disease , whether direct symptom diseases reaction live chronic progressive disease . It well establish health psychology literature , however , interaction physical health psychological health bidirectional ; , physical health affect u emotionally ( e.g . chronic pain contribute depression ) , psychological health affect u physically ( e.g . anxiety contribute feeling chest pain ) . It thus critically important pay attention emotional psychological symptom associate lysosomal storage disease , include Morquio , expand treatment standard care include mental health treatment , necessary . The first step understand treat psychological condition Morquio disease determine natural occurrence psychological symptom population comparison non-medical population . As little do regard , pilot study document occurrence rate psychological issue overall quality life patient Morquio first item order focus study . Approximately 20 patient Morquio disease invite participate , recruit Emory 's Lysosomal Storage Disease Center , well attendance Morquio support group relevant regional , national and/or international meeting . Once consent , patient ask complete three different self-report questionnaire , include Achenbach System Empirically Based Assessment ( ASEBA ) Adult Self-Report ( ASR ) Older Adult Self-Report ( OASR ) questionnaire , Short Form 36-item Health Questionnaire ( SF-36 ) , Brief Pain Inventory ( BPI ) . Group aggregate data report ; individual questionnaire content result hold confidential , except accordance Georgia law relate report child elder abuse , suicidal and/or homicidal intent . Completion questionnaires complete subject ' participation pilot study .</brief_summary>
	<brief_title>Psychological Concomitants Morquio Syndrome ( The MAP Study )</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<criteria>1 . Documented clinical diagnosis MPS IV base clinical sign symptom MPS IV document reduce fibroblast leukocyte GALNS enzyme activity genetic test confirm diagnosis MPS IV . 2 . Patient least 18 year old . 3 . Patient currently receive enzyme replacement therapy MPS IV . 4 . Patient must provide write , informed consent prior study participation . 1 . Previous treatment ERT 2 . Previous hematopoietic stemcell transplant 3 . Patient clinically significant disease ( exception symptom Morquio ) , include clinically significant immunologic , pulmonary , neurologic , renal disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion investigator , would confound effect Morquio upon study variable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Morquio</keyword>
	<keyword>Mucopolysaccharidosis IV</keyword>
	<keyword>Psychological health</keyword>
</DOC>